Drug Profile
SL 251039
Latest Information Update: 16 May 2002
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Alpha 1 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Urinary incontinence
Most Recent Events
- 16 May 2002 Discontinued - Phase-II for Urinary incontinence (unspecified route)
- 19 Feb 2001 Phase-II clinical trials for Urinary incontinence (Unknown route)
- 08 Nov 2000 New profile